Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
Tumor Progression02:07

Tumor Progression

6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Blood neoplasia·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026
Same author

Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.

Transplantation and cellular therapy·2026
Same author

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Blood advances·2026
Same author

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Blood advances·2026
Same author

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Blood advances·2026

Related Experiment Video

Updated: Nov 10, 2025

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

535

Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.

David A Bond1, Peter Martin2, Kami J Maddocks1

  • 1Division of Hematology, The Ohio State University, Columbus, OH 43210, USA.

Journal of Clinical Medicine
|April 3, 2021
PubMed
Summary

Mantle cell lymphoma (MCL) treatments for relapsed disease are expanding, including Bruton

Keywords:
cellular therapiesearly progression of diseasenovel agentsrelapsed or refractory mantle cell lymphoma

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Related Experiment Videos

Last Updated: Nov 10, 2025

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

535
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Mantle cell lymphoma (MCL) treatment landscape is evolving with new therapies for relapsed disease.
  • Chemo-immunotherapy is a common frontline treatment, while targeted therapies are available for relapsed MCL.
  • Sequencing and prioritizing complex treatment options for relapsed MCL present challenges.

Purpose of the Study:

  • To review current evidence for approved therapies in relapsed MCL.
  • To discuss the sequencing of these therapies.
  • To explore future directions, including combination strategies and novel agents.

Main Methods:

  • Comprehensive literature review of approved treatments for relapsed MCL.
  • Analysis of efficacy, toxicity, and dosing of Bruton's tyrosine kinase inhibitors (BTKi), lenalidomide, bortezomib, and CAR-T therapies.
  • Discussion of off-label use of venetoclax and emerging treatment strategies.

Main Results:

  • BTKi (ibrutinib, acalabrutinib, zanubrutinib) show high response rates but vary in toxicity and dosing.
  • Lenalidomide and bortezomib are effective as monotherapy or combination agents.
  • Anti-CD19 CAR-T therapy, such as brexucabtagene autoleucel, is a highly effective option for relapsed MCL.

Conclusions:

  • Multiple effective treatment options exist for relapsed MCL, necessitating careful sequencing.
  • Further research is needed on venetoclax efficacy, especially post-BTKi treatment.
  • Combination therapies and novel agents hold promise for future MCL treatment strategies.